Zhitong Financial App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Xinxiang Changle Pharmaceutical Co., Ltd. (“Changle Pharmaceutical”), a holding subsidiary of the company, recently received the approval and issuance of the “Drug Supplement Application Approval Notice” for isazolam tablets from the State Drug Administration to approve Changle Pharmaceutical's product to pass the consistent evaluation of generic drug quality and efficacy.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Xinxiang Changle Pharmaceutical Co., Ltd. (“Changle Pharmaceutical”), a holding subsidiary of the company, recently received the approval and issuance of the “Drug Supplement Application Approval Notice” for isazolam tablets from the State Drug Administration to approve Changle Pharmaceutical's product to pass the consistent evaluation of generic drug quality and efficacy.